-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Reiterates Buy on Artiva Biotherapeutics, Maintains $41 Price Target

Benzinga·06/08/2026 15:45:34
Listen to the news
Needham analyst Gil Blum reiterates Artiva Biotherapeutics (NASDAQ:ARTV) with a Buy and maintains $41 price target.